Search hospitals > Alberta > CALGARY
University of Calgary
Claim this profileCALGARY, Alberta T2N 4Z6
Global Leader in Crohn's Disease
Global Leader in Hepatitis
Conducts research for Diabetes
Conducts research for Heart Failure
Conducts research for Stroke
420 reported clinical trials
51 medical researchers
Summary
University of Calgary is a medical facility located in CALGARY, Alberta. This center is recognized for care of Crohn's Disease, Hepatitis, Diabetes, Heart Failure, Stroke and other specialties. University of Calgary is involved with conducting 420 clinical trials across 543 conditions. There are 51 research doctors associated with this hospital, such as Robert S Sheldon, MD, PhD, John Anderson, MD, Prism Schneider, MD, and Eric Smith, MD.Top PIs
Robert S Sheldon, MD, PhDUniversity of Calgary3 years of reported clinical research
Studies Syncope
Studies Fainting
10 reported clinical trials
13 drugs studied
John Anderson, MDClinical Research Center of Alabama5 years of reported clinical research
Studies Angioedema
Studies Hereditary Angioedema
9 reported clinical trials
11 drugs studied
Prism Schneider, MDFoothills Medical Centre6 years of reported clinical research
Studies Hip Fracture
Studies Unintentional Home Injuries
9 reported clinical trials
13 drugs studied
Eric Smith, MDUniversity of Calgary5 years of reported clinical research
Studies Alzheimer's Disease
Studies Vanishing White Matter Disease
7 reported clinical trials
8 drugs studied
Clinical Trials running at University of Calgary
Stroke
Crohn's Disease
Depression Treatment
Postural Orthostatic Tachycardia Syndrome
Heart Failure
Depression
Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Cancer
Tenecteplase
for Stroke
This domain has a prospective, randomized, controlled, open-label, parallel group with blinded endpoint assessment (PROBE) design. Up to 4,000 patients with presumed acute ischemic stroke (AIS) will be followed for 90 days (or until death, if prior to 90 days). The end of the trial is defined as the date that all participants have completed their Day 90 assessment. This domain aim is to efficiently, reliably, and simultaneously, determine the comparative effectiveness of intravenous thrombolysis (IVT) using standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) in all patients who present to hospital with acute ischemic stroke and are considered for intravenous thrombolysis. In addition, this domain also seeks to study standard-dose intravenous tenecteplase (0.25 mg/kg body weight), vs. low-dose intravenous tenecteplase (0.18 mg/kg body weight) vs. no TNK upfront with rescue IA TNK if necessary (in those eligible for emergency EVT) and no TNK upfront in those who have taken DOACs during the preceding 24 hours. This domain therefore seeks to generate more robust randomized evidence to guide clinicians in their decisions over the balance of risks and treatment with intravenous thrombolysis with tenecteplase wherever such evidence is currently insufficient. This domain will currently evaluate four research questions in relation to the use of IVT with tenecteplase: 1. In patients with recent (24 hours) intake of a standard-dose direct oral anticoagulant (DOAC), how should IVT be used? - Use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg) or not at all. 2. In patients planned to be treated with endovascular thrombectomy, how should tenecteplase be used? -Treat with IV tenecteplase (standard- or low-dose) or not at all. 3. In any patient receiving IVT, what is the optimal dose of tenecteplase? - use standard-dose (0.25 mg/kg body weight) or low-dose tenecteplase (0.18 mg/kg). 4. To what extent is the treatment effect of standard- vs. low-dose tenecteplase modified by key patient characteristics, such as diabetes, prior antiplatelet therapy, renal failure, or frailty, old age or having a heavy burden of cerebral small vessel disease on brain imaging.
Recruiting2 awards Phase 3
WATCHMAN Device
for Atrial Fibrillation
LAAOS-4 aims to determine if catheter-based endovascular left atrial appendage occlusion prevents ischemic stroke or systemic embolism in participants with atrial fibrillation, who remain at high risk of stroke, despite receiving ongoing treatment with oral anticoagulation.
Recruiting1 award N/A3 criteria
Blood Pressure Control
for Stroke
Several clinical trials have produced variable conclusions regarding the effects of intensive blood pressure (BP) lowering in post-EVT acute ischaemic stroke (AIS) patients. Although two trials indicate harm from very intensive target-based treatment (SBP \<130 mmHg), the others neutral effects in the SBP range 140-160 mmHg. The ENCHANTED3/MT domain of the ACT-GLOBAL platform trial aims to test different approaches to the treatment of elevated SBP in post-EVT AIS patients to find an optimal BP management strategy. ENCHANTED3/MT will randomize (1:1:1) up to 2,000 patients with SBP ≥150 mmHg post-EVT to conservative (no or minimal SBP reduction by 5-10mmHg or a target of 175-180mmHg if very-high baseline SBP \[≥180mmHg\]), moderate (SBP reduction by 10-20mmHg or a target of 160 ± 5, whichever is higher; no control if low-high baseline SBP \[150-160mmHg\]), or intensive (SBP reduction by 30-50mmHg or a target of 140±5 mmHg, whichever is higher) BP management.
Recruiting1 award N/A2 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Calgary?
University of Calgary is a medical facility located in CALGARY, Alberta. This center is recognized for care of Crohn's Disease, Hepatitis, Diabetes, Heart Failure, Stroke and other specialties. University of Calgary is involved with conducting 420 clinical trials across 543 conditions. There are 51 research doctors associated with this hospital, such as Robert S Sheldon, MD, PhD, John Anderson, MD, Prism Schneider, MD, and Eric Smith, MD.
Where is University of Calgary located?
**University of Calgary Hospital**
- **Address:** 3330 Hospital Dr NW, Calgary, AB T2N 4N1.
- For the most efficient route, consider using real-time driving directions from Waze or MapQuest.
Who should I call to ask about financial aid or insurance network?
**University of Calgary Financial Assistance Contact Information:**
- **Financial Assistance and Loans Office:**
- **Address:** 2500 University Drive NW, Calgary, AB, Canada T2N 1N4
- **Email:** riskmgmt@ucalgary.ca
- **Phone:** 403.210.9502
- **Hours:** 8:30 a.m. - noon & 1 p.m. - 4:30 p.m., Monday - Friday (Excluding lunch hours and statutory holidays)
- **Risk Management and Insurance Department:**
- **Address:** Math Sciences, Room 255, 2500 University Drive N.W., Calgary, Alberta T2N 1N4
- **Email:** riskmgmt@ucalgary.ca
- **Phone:** 403.210.9502
- **Hours:** 8:30 a.m. - noon & 1 p.m. - 4:30 p.m., Monday - Friday (Excluding lunch hours and statutory holidays)
- **Emergency Financial Assistance:**
- Contact an Enrolment Services advisor for emergency financial assistance and application access.
What insurance does University of Calgary accept?
The University of Calgary accepts the following insurance plans:
1. **Alberta Health Care Insurance Plan (AHCIP)** - Covers basic services such as doctor visits, laboratory tests, and hospital costs. Does not include prescription drugs, dental, vision care, or ambulance transport.
2. **Students Union (SU) Health and Dental Plan** - Available to full-time undergraduate students, covering prescription drugs, dental services, vision care, ambulance transport, and more.
3. **Graduate Students Association (GSA) Health & Dental Plan** - For full-time graduate students, offering similar coverage as the SU Health and Dental Plan.
4. **Manulife University of Calgary Health and Dental Insurance** - Provides extended health care including prescriptions, dental care, vision, massage therapy, and more.
5. **Private medical insurance plans** - Required for international exchange and visiting students, as they are not eligible for AHCIP.
What awards or recognition has University of Calgary received?
The University of Calgary Hospital, located in Calgary, Alberta, is renowned for its exceptional research and care initiatives. It is particularly noted for the "One Child Every Child" research initiative, focused on the health and empowerment of children. The hospital's commitment to healthcare excellence is further underscored by the induction of eight of its researchers into the Canadian Academy of Health Sciences.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.